Niacin-laropiprant was associated with an increased incidence of disturbances in diabetes control that were considered to be serious ( absolute excess as compared with placebo , 3.7 percentage points ; P < 0.001 ) and with an increased incidence of diabetes diagnoses ( absolute excess , 1.3 percentage points ; P < 0.001 ) , as well as increases in serious adverse events associated with the gastrointestinal system ( absolute excess , 1.0 percentage point ; P < 0.001 ) , musculoskeletal system ( absolute excess , 0.7 percentage points ; P < 0.001 ) , skin ( absolute excess , 0.3 percentage points ; P = 0.003 ) , and unexpectedly , infection ( absolute excess , 1.4 percentage points ; P < 0.001 ) and bleeding ( absolute excess , 0.7 percentage points ; P < 0.001 ) .